These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 31513706)

  • 1. A Call to Action: HCV Treatment of People Who Inject Drugs in the United States.
    Norton BL; Litwin AH
    Clin Infect Dis; 2020 May; 70(11):2366-2368. PubMed ID: 31513706
    [No Abstract]   [Full Text] [Related]  

  • 2. Progress Towards Elimination of Hepatitis C Infection Among People Who Inject Drugs in Australia: The ETHOS Engage Study.
    Valerio H; Alavi M; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Holden J; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Hayllar J; Reid D; Gorton C; Lam T; Dore GJ; Grebely J
    Clin Infect Dis; 2021 Jul; 73(1):e69-e78. PubMed ID: 32421194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. It's Not Them, It's Us: Hepatitis C Reinfection Following Successful Treatment Among People Who Inject Drugs.
    Barocas JA
    Clin Infect Dis; 2021 Apr; 72(8):1401-1403. PubMed ID: 32166311
    [No Abstract]   [Full Text] [Related]  

  • 4. Hepatitis C treatment outcomes among people who inject drugs accessing harm reduction settings in Kenya.
    Akiyama MJ; Riback LR; Nyakowa M; Musyoki H; Lizcano JA; Muller A; Zhang C; Walker JG; Stone J; Vickerman P; Cherutich P; Kurth AE
    J Viral Hepat; 2022 Aug; 29(8):691-694. PubMed ID: 35274394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. More intensive hepatitis C virus care models promote adherence among people who inject drugs with active drug use: The PREVAIL study.
    Heo M; Pericot-Valverde I; Niu J; Norton BL; Akiyama MJ; Nahvi S; Arnsten JH; Litwin AH
    J Viral Hepat; 2023 Feb; 30(2):172-175. PubMed ID: 36197920
    [No Abstract]   [Full Text] [Related]  

  • 6. Alcohol Use Disorder and Hepatitis C Prevention and Care in People Who Inject Drugs: The State of Play.
    Marcellin F; Jaquet A; Lazarus JV; Molina P; Carrieri P
    Semin Liver Dis; 2021 May; 41(2):109-116. PubMed ID: 32851613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experience with viral hepatitis C treatment among people who inject drugs and participate in a methadone substitution treatment program.
    Krekulová L; Vavrinčíková L
    Epidemiol Mikrobiol Imunol; 2021; 70(1):18-25. PubMed ID: 33853334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study.
    Alavi M; Grebely J; Micallef M; Dunlop AJ; Balcomb AC; Day CA; Treloar C; Bath N; Haber PS; Dore GJ;
    Clin Infect Dis; 2013 Aug; 57 Suppl 2():S62-9. PubMed ID: 23884068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated treatment of hepatitis C virus infection among people who inject drugs: study protocol for a randomised controlled trial (INTRO-HCV).
    Fadnes LT; Aas CF; Vold JH; Ohldieck C; Leiva RA; Chalabianloo F; Skurtveit S; Lygren OJ; Dalgård O; Vickerman P; Midgard H; Løberg EM; Johansson KA;
    BMC Infect Dis; 2019 Nov; 19(1):943. PubMed ID: 31703669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France.
    Cousien A; Tran VC; Deuffic-Burban S; Jauffret-Roustide M; Mabileau G; Dhersin JS; Yazdanpanah Y
    J Viral Hepat; 2018 Oct; 25(10):1197-1207. PubMed ID: 29660211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study.
    Midgard H; Hajarizadeh B; Cunningham EB; Conway B; Backmund M; Bruggmann P; Bruneau J; Bourgeois S; Dunlop A; Foster GR; Hellard M; Robaeys G; Thurnheer MC; Weltman M; Amin J; Marks PS; Quiene S; Dore GJ; Dalgard O; Grebely J;
    Int J Drug Policy; 2017 Sep; 47():230-238. PubMed ID: 28633998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Barriers to antiviral treatment in hepatitis C infected intravenous drug users.
    Gazdag G; Horvath G; Szabo O; Ungvari GS
    Neuropsychopharmacol Hung; 2010 Dec; 12(4):459-62. PubMed ID: 21220790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. People with Hepatitis C Who Inject Drugs - Underserved, Not Undeserving.
    Dore GJ; Trooskin S
    N Engl J Med; 2020 Aug; 383(7):608-611. PubMed ID: 32786185
    [No Abstract]   [Full Text] [Related]  

  • 14. The Potential Reach of Opioid Substitution Settings to Deliver HCV Care to People Who Inject Drugs in Australia.
    Butler K; Day C; Dietze P; Bruno R; Alati R; Burns L
    J Subst Abuse Treat; 2015 Nov; 58():90-4. PubMed ID: 26117080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. We Must Do Better: Addressing HCV Treatment Barriers in Persons Who Inject Drugs in the United States.
    Trooskin SB; Dore G; Kostman J
    J Infect Dis; 2020 Nov; 222(Suppl 9):S773-S781. PubMed ID: 33245349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment for chronic hepatitis C in a cohort of opiate substitution therapy recipients in three Swedish cities - completion rates and efficacy.
    Jerkeman A; Norkrans G; Lidman C; Westin J; Lagging M; Frimand J; Simonsberg C; Kakko J; Widell A; Björkman P
    Eur J Gastroenterol Hepatol; 2014 May; 26(5):523-31. PubMed ID: 24637496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Onsite treatment of HCV infection with direct acting antivirals within an opioid treatment program.
    Butner JL; Gupta N; Fabian C; Henry S; Shi JM; Tetrault JM
    J Subst Abuse Treat; 2017 Apr; 75():49-53. PubMed ID: 28237054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C Virus Reinfection Rate Among Persons Who Use Drugs and Are Maintained on Medication Treatment for Opioid Use Disorder.
    Springer SA
    Clin Infect Dis; 2020 Jun; 70(12):2703-2705. PubMed ID: 31346595
    [No Abstract]   [Full Text] [Related]  

  • 19. Prevalence of hepatitis C and pre-testing awareness of hepatitis C status in 1500 consecutive PWID participants at the Stockholm needle exchange program.
    Kåberg M; Hammarberg A; Lidman C; Weiland O
    Infect Dis (Lond); 2017 Oct; 49(10):728-736. PubMed ID: 28574295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-reported outcomes of the Treatment and Prevention Study: A real-world community-based trial of direct-acting antivirals for hepatitis C among people who inject drugs.
    Goutzamanis S; Spelman T; Harney B; Dietze P; Stoove M; Higgs P; Thompson A; Doyle JS; Hellard M
    J Viral Hepat; 2021 Jul; 28(7):1068-1077. PubMed ID: 33880820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.